LLY

1,086.9

+2.13%↑

JNJ

224.41

+0.52%↑

ABBV

218.39

+2.61%↑

UNH

384

+2.26%↑

MRK

115.88

+0.27%↑

LLY

1,086.9

+2.13%↑

JNJ

224.41

+0.52%↑

ABBV

218.39

+2.61%↑

UNH

384

+2.26%↑

MRK

115.88

+0.27%↑

LLY

1,086.9

+2.13%↑

JNJ

224.41

+0.52%↑

ABBV

218.39

+2.61%↑

UNH

384

+2.26%↑

MRK

115.88

+0.27%↑

LLY

1,086.9

+2.13%↑

JNJ

224.41

+0.52%↑

ABBV

218.39

+2.61%↑

UNH

384

+2.26%↑

MRK

115.88

+0.27%↑

LLY

1,086.9

+2.13%↑

JNJ

224.41

+0.52%↑

ABBV

218.39

+2.61%↑

UNH

384

+2.26%↑

MRK

115.88

+0.27%↑

Home・Stock List・10X Genomics Inc (Class A)

10X Genomics Inc (Class A)

Closed

SectorHealthcare

30.63 4.97

Buy Sell

Overview

Share price change

24h

Current

Min

Max

31.12

Key metrics
By Trading Economics
Income	2.8M -13M
Sales	-15M 151M
EPS	0.07
Profit margin	-8.93
Employees	1,178
EBITDA	2.5M -17M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	-17.2% downside

Dividends
By Dow Jones
Next Earnings	6 Aug 2026

Market Stats
By TradingEconomics
Market Cap	964M 3.8B
Previous open	25.66
Previous close	30.63

News Sentiment

By Acuity

50%

147 / 344 Healthcare

10X Genomics Inc (Class A) Chart

Past performance is not a reliable indicator of future results.

Related News

2 Jun 2026, 20:30 UTC

Earnings

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 Jun 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 Jun 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 Jun 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 Jun 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 Jun 2026, 23:01 UTC

Acquisitions, Mergers, Takeovers

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 Jun 2026, 23:01 UTC

Acquisitions, Mergers, Takeovers

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 Jun 2026, 23:00 UTC

Acquisitions, Mergers, Takeovers

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 Jun 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 Jun 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 Jun 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 Jun 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 Jun 2026, 21:00 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 Jun 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2 Jun 2026, 20:46 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 Jun 2026, 20:38 UTC

Earnings

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 Jun 2026, 20:21 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 Jun 2026, 20:12 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Product Rev $594M

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Loss $177M >PANW

Peer Comparison

Price change

10X Genomics Inc (Class A) Forecast

Price Target

By TipRanks

-17.2% downside

12 Months Forecast

Average 24.5 USD -17.2%

High 32 USD

Low 20 USD

Based on 10 Wall Street analysts offering 12 month price targets for10X Genomics Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to 10X Genomics Inc (Class A) - Dist in the past 3 months.

Sentiment

By Acuity

147 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.